Search
SC12267
go.drugbank.com/drugs/DB05125InvestigationalSC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis.
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalWhen administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).
INCB3284
go.drugbank.com/drugs/DB05130ExperimentalINCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.
VP025
go.drugbank.com/drugs/DB05133ExperimentalIt is considered to be a systemic anti-inflammatory and neuroprotective agent. … VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.
AdPEDF
go.drugbank.com/drugs/DB05138ExperimentalAdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...
OXI-4503
go.drugbank.com/drugs/DB05143InvestigationalOXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. … OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA).
Synonyms: Combretastatin A-1 bis(phosphate)PEV3A
go.drugbank.com/drugs/DB05144InvestigationalPEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302.
TH0318
go.drugbank.com/drugs/DB05145ExperimentalTH0318 is a stabilized analogue of human GLP-1 (glucagon-like peptide-1) under investigation for the treatment of type 2 diabetes.
XL844
go.drugbank.com/drugs/DB05149InvestigationalXL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.